WALVAX(300142)2023-03-29 16:00Financial Performance - The total revenue for 2022 was 1.5 billion CNY, representing a year-on-year increase of 15%[3]. - The company achieved a net profit of 300 million CNY in 2022, up 20% compared to the previous year[3]. - The company's operating revenue for 2022 was ¥5,086,445,195.10, representing a 46.89% increase compared to ¥3,462,831,094.14 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥728,652,009.34, a 70.35% increase from ¥427,747,681.59 in 2021[12]. - The net profit after deducting non-recurring gains and losses was ¥859,124,544.51, up 45.33% from ¥591,146,772.49 in 2021[12]. - The basic earnings per share for 2022 was ¥0.4546, a 66.70% increase from ¥0.2727 in 2021[12]. - The cash flow from operating activities for 2022 was ¥1,201,491,008.09, a 70.36% increase from ¥705,276,750.42 in 2021[12]. - The company reported a quarterly revenue of ¥1,692,153,912.48 in Q2 2022, which was the highest among the four quarters[14]. - The company reported a total revenue of ¥1.86 billion from its subsidiary Guangzhou Watson, with a net profit of approximately ¥62.64 million[94]. - The company reported a total shareholding of 63,005,970 shares at the end of the reporting period, with a net decrease of 10,608,625 shares due to various transactions[115]. Market Expansion and Product Development - User data indicated a 25% increase in vaccine sales volume, with a total of 10 million doses sold in 2022[3]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[3]. - New product development includes a novel mRNA vaccine, expected to enter clinical trials in Q3 2023[3]. - Future guidance estimates a revenue growth of 20% for 2023, driven by new product launches and market expansion[3]. - The company is actively pursuing internationalization and import substitution strategies to enhance its market presence[31]. - The company aims to accelerate the development of new vaccines, including mRNA vaccines for COVID-19 variants and a nine-valent HPV vaccine, to meet market demand[98]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[126]. - The company is committed to a comprehensive internationalization strategy, aiming to complete WHO pre-certification for key products and expand into international markets[98]. Research and Development - The company is exploring strategic acquisitions to enhance its R&D capabilities, with a budget of 500 million CNY allocated for this purpose[3]. - The company’s R&D efforts include multiple vaccines in various clinical stages, including the nine-valent HPV vaccine and the new mRNA vaccines for COVID-19[36]. - The company has a stable R&D team with over 210 employees holding doctoral or master's degrees, enhancing its innovation capabilities[46]. - The company is committed to building a smart factory through digital integration of production quality management and cold chain logistics monitoring[39]. - The company has established a modern vaccine production base in Yuxi, Yunnan, capable of large-scale production of multiple vaccine varieties, adhering to WHO PQ pre-certification standards[46]. - The company is actively involved in the research and development of new products, particularly in the vaccine sector[120]. Financial Management and Investments - The company has received government subsidies amounting to ¥111,110,270.61 in 2022, which was an increase compared to ¥71,773,119.15 in 2021[18]. - The company has made significant equity investments, including ¥100 million in Shanghai Zerun Biotechnology Co., holding a 56.61% stake, and ¥50 million in Guangzhou Watson Health Technology Co., acquiring a 100% stake[75]. - The total investment amount for the reporting period was ¥660 million, a decrease of 60.23% compared to ¥1.66 billion in the same period last year[74]. - The company has a long-term commitment to avoid related transactions with Watson Bio after the completion of the asset restructuring[192]. - The company has a commitment to ensure that any future stock incentive plans are linked to the execution of its compensation measures[193]. Corporate Governance and Compliance - The company has established a comprehensive quality management system to ensure the delivery of qualified, safe, and effective drugs to end users, adhering to various regulations such as the Drug Administration Law and Vaccine Management Law[101]. - The company has implemented strict anti-fraud, anti-money laundering, and anti-bribery management systems to mitigate compliance risks[169]. - The company has established a risk management department in its subsidiary to identify, prevent, and control risks in the production and quality management processes, implementing risk-based management throughout the production process[102]. - The company has maintained a stable governance structure, ensuring that shareholders, especially minority shareholders, can exercise their rights effectively[104]. - The company has a dispersed shareholding structure, with no single shareholder able to control the board or the company[109]. Environmental Responsibility - The company has implemented a series of environmental protection projects, including the mRNA COVID-19 vaccine industrialization project, which received approval in August 2021 and passed environmental acceptance in November 2022[177]. - The company has established pollution control facilities, including one wastewater treatment facility and two air pollution control facilities, all of which are operating normally[179]. - The company is committed to maintaining compliance with environmental regulations and enhancing corporate governance to protect shareholder interests, particularly for minority shareholders[175]. - The company has received multiple environmental impact assessment approvals for various projects, ensuring compliance with local environmental regulations[177]. - The company aims to create a production system with minimal environmental impact, promoting green and low-carbon development[185]. Shareholder Relations and Communication - The company emphasizes the importance of maintaining investor relations and has adhered to its investor relations management system throughout the reporting period[106]. - The company conducted a performance online briefing on April 6, 2022, to enhance investor understanding of its development strategy and operational management[106]. - The company maintains regular communication with investors through various channels, ensuring timely responses to inquiries[108]. - The company has established designated media for information disclosure, ensuring equal access to information for all shareholders[108]. - The company held its 2021 Annual General Meeting on April 12, 2022, with an investor participation rate of 18.67%[111]. Employee Management and Development - The total number of employees at the end of the reporting period was 2,249, with 1,602 in production roles[141]. - The company has implemented a new performance management system in 2022 to enhance the connection between organizational and individual performance results[143]. - The company has established a talent management project, establishing 6 talent standard models to optimize its talent management system[145]. - The company has expanded its training programs to include a wider range of participants, enhancing understanding of compliance and operational standards among subsidiary staff[175]. - The company has implemented employee stock ownership and stock option incentive plans to enhance talent retention and organizational cohesion[143].